Filing Flows › HCW Biologics (HCWB) › Q4 2024
HCW Biologics (HCWB) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 28, 2025
HCW Biologics (HCWB) reported revenue of $395K for the fourth quarter 2024 (Q4 2024), -70% from a year earlier and -7% from the quarter before. Operating margin was -797.2%, net loss $3.4M (854.4% of revenue).
HCW Biologics, Q4 2024: revenue $395K (-70% year over year), operating margin -797.2%, net loss $3.4M, operating cash flow −$2.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $395K | -7% | -70% |
| Operating profit | −$3.1M | — | — |
| Net earnings | −$3.4M | — | — |
| Operating cash flow | −$2.8M | — | — |
What changed
Revenue was $395K in Q4 2024, down 70% year over year and down 7% from the previous quarter.
Gross margin was 20.0%, up 0.9 points from a year earlier. Operating costs exceeded revenue by $3.1M, an operating margin of -797.2%. Operating expenses fell 71% while revenue fell 70%. The quarter ended with a net loss of $3.4M, narrower than the previous quarter's $3.9M loss.
Operating cash flow was −$2.8M. Non-cash charges added back $683K of depreciation and amortization and $292K of share-based compensation. Working capital and other items used $436K. Capital expenditures of $113K exceeded it, leaving free cash flow of −$2.9M.
Questions
What was HCW Biologics' revenue in the fourth quarter 2024?
HCW Biologics (HCWB) reported revenue of $395K for the fourth quarter 2024 (Q4 2024), -70% from a year earlier and -7% from the quarter before.
Was HCW Biologics profitable in the fourth quarter 2024?
Operating loss was $3.1M (-797.2% of revenue) and net loss $3.4M.
Source: HCW Biologics 10-K on SEC EDGAR.